PRDM13 and breast carcinoma: Four HMTs (ASH1L, SETDB1, and SMYD3) presented higher amplification frequencies in basal-like breast cancer (a subtype of TNBC) while eight HMT expression levels (EZH1, SMYD3, EHMT1, SETD7, PRDM4, SETD3, SETD1B, and PRDM6) were significantly downregulated and twelve HMT expression levels (EZH2, PRDM15, PRDM13, SMYD2, SMYD5, SUV39H1, SUV39H2, EHMT2, WHSC1, SETD8, SETDB and SETD6) were significantly up-regulated comparing basal-like to other breast cancer subtypes [99].